Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

JNJ-5322

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

J&J

Drug class:

CD3 agonist, BCMA inhibitor, GPRC5D inhibitor

Related drugs:

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

linvoseltamab (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

ABBV-383 IV (0)

huCD33-BsAb (0)

›

GPRC5D expression	Multiple Myeloma	GPRC5D expression	Multiple Myeloma	JNJ-5322 Sensitive: D – Preclinical JNJ-5322 Sensitive : D	JNJ-5322 Sensitive: D – Preclinical JNJ-5322 Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	JNJ-5322 Sensitive: D – Preclinical JNJ-5322 Sensitive : D	JNJ-5322 Sensitive: D – Preclinical JNJ-5322 Sensitive : D
TNFRSF17 expression + GPRC5D expression	Multiple Myeloma	TNFRSF17 expression + GPRC5D expression	Multiple Myeloma	JNJ-5322 Sensitive: D – Preclinical JNJ-5322 Sensitive : D	JNJ-5322 Sensitive: D – Preclinical JNJ-5322 Sensitive : D